Tim Precious was named CEO of NuVision Biotherapies in May 2026. He brings extensive experience in the optical and ophthalmic space, having led businesses ranging from £35m to £250m. Tim spent the majority of his career at EssilorLuxottica in a series of progressively senior roles across the UK & Ireland, Nordics, and Benelux.
Tim now drives NuVision’s transition to a commercially-focused organisation, expanding OmnigenⓇ and OmniLenzⓇ across the UK, Middle East, Nordics, and Europe.
